Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

Novel subunit vaccine against chlamydial infection

FY 2014-15

Summary
Chlamydia trachomatis is a significant pathogen in humans and a major cause of disease burden worldwide. It is responsible for over 6 million cases of blindness in developing countries annually, and is the most common sexually transmitted bacterial infection in Canada. Sexually transmitted C. trachomatis infections can lead to a number of complications, including pelvic inflammatory disease, subsequently leading to infertility.Alarmingly, studies have shown that up to 90% of women with C. trachomatis infections do not know they are infected, making them even more susceptible to developing serious complications. While vaccines are the preferred health intervention to curb infectious diseases, antibiotics are currently our only arsenals against C. trachomatis infections. As concerns regarding antibiotic resistance grow, greater efforts are needed to develop safe and effective vaccines to prevent infection.A crucial component of the chlamydial infection machinery is the type III secretion apparatus. Three proteins from this apparatus are promising candidates for a vaccine against C. trachomatis . We believe that miceimmunized with a vaccine consisting of these proteins will be protected from Chlamydia infections and its associated pelvic inflammatory disease. Mice will be immunized with different combinations of the three proteins and two adjuvants, substances that enhance the ability of proteins to induce an immune response. Following immunization, mice will be infected with Chlamydia . Mice will then be periodically monitored for Chlamydia levels and reproductive pathology.Positive results from our studies can identify novel C. trachomatis proteins and bring new vaccine candidates into clinical trials.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
331314
Name
Liang Steven
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Novel subunit vaccine against chlamydial infection
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chlamydia Trachomatis; Copb; Copd; Ct584; Immune Response; Vaccine
Abstract
Chlamydia trachomatis is a significant pathogen in humans and a major cause of disease burden worldwide. It is responsible for over 6 million cases of blindness in developing countries annually, and is the most common sexually transmitted bacterial infection in Canada. Sexually transmitted C. trachomatis infections can lead to a number of complications, including pelvic inflammatory disease, subsequently leading to infertility.Alarmingly, studies have shown that up to 90% of women with C. trachomatis infections do not know they are infected, making them even more susceptible to developing serious complications. While vaccines are the preferred health intervention to curb infectious diseases, antibiotics are currently our only arsenals against C. trachomatis infections. As concerns regarding antibiotic resistance grow, greater efforts are needed to develop safe and effective vaccines to prevent infection.A crucial component of the chlamydial infection machinery is the type III secretion apparatus. Three proteins from this apparatus are promising candidates for a vaccine against C. trachomatis . We believe that miceimmunized with a vaccine consisting of these proteins will be protected from Chlamydia infections and its associated pelvic inflammatory disease. Mice will be immunized with different combinations of the three proteins and two adjuvants, substances that enhance the ability of proteins to induce an immune response. Following immunization, mice will be infected with Chlamydia . Mice will then be periodically monitored for Chlamydia levels and reproductive pathology.Positive results from our studies can identify novel C. trachomatis proteins and bring new vaccine candidates into clinical trials.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Liang, Steven
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~